Prospective Grant of Exclusive License: Development of a Diagnostic Tool for Diagnosing Benign Versus Malignant Thyroid Lesions, 42504-42505 [2012-17497]
Download as PDF
<![CDATA[
42504
Federal Register / Vol. 77, No. 139 / Thursday, July 19, 2012 / Notices
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 13, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: July 13, 2012.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–17512 Filed 7–18–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2012–17492 Filed 7–18–12; 8:45 am]
Prospective Grant of Exclusive
License: Development of a Diagnostic
Tool for Diagnosing Benign Versus
Malignant Thyroid Lesions
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
emcdonald on DSK67QTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: CMIP and MEDI Continuous
Submission Review Panel.
Date: July 27, 2012.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Guo Feng Xu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5122,
MSC 7854, Bethesda, MD 20892, 301–237–
9870, xuguofen@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
VerDate Mar<15>2010
15:07 Jul 18, 2012
Jkt 226001
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in PCT Patent Application
No. PCT/US2005/12289, U.S. Patent No.
7,901,881, U.S. Patent Application No.
13/024,845 and foreign equivalents
thereof entitled ‘‘Diagnostic Tool for
Diagnosing Benign Versus Malignant
Thyroid Lesions’’ (HHS Ref. No. E–124–
2004/0,1,2) and PCT Patent Application
No. PCT/US2008/010139 and U.S.
Patent Application No. 12/675,209
entitled ‘‘Diagnostic Tool for Diagnosing
Benign Versus Malignant Thyroid
Lesions’’ (HHS Ref. No. E–326–2007/0)
to Veracyte, Inc., which is located in
San Francisco, California. The patent
rights in these inventions have been
assigned to the United States of
America.
Other than license applications
submitted as objections to this Notice of
Intent to Grant an Exclusive License, no
further license applications will be
considered for the exclusive field of use
set forth below if Veracyte, Inc. is
granted an exclusive license pursuant to
this Notice of Intent to Grant an
Exclusive License. The prospective
exclusive license territory may be
worldwide and the field of use may be
limited to the use of Licensed Patent
Rights for the diagnosis and prognosis of
thyroid cancer.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
August 20, 2012 will be considered, in
addition to the current non-exclusive
applications under consideration, for
the prospective license territory and
SUMMARY:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
field of use to be granted under the
contemplated exclusive patent license.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Whitney A. Hastings,
Ph.D., Licensing and Patenting Manager,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 451–
7337; Facsimile: (301) 402–0220; Email:
hastingw@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This
technology is based on the discovery of
differentially expressed thyroid (DET)
genes and their encoded proteins whose
expression levels can be correlated to
benign or malignant states in a thyroid
cell. Specifically, this data arose from a
microarray analysis of genes expressed
in the eight subtypes of thyroid tumors
that are typically difficult to diagnose by
cytology of fine needle aspiration (FNA)
biopsies. Analysis of the (DET) genes
led to the development of 6 gene and 10
gene models that distinguish benign vs.
malignant papillary thyroid tumors.
Subsequently, a 72 gene model has been
developed for diagnosing less common
forms of thyroid cancer such as
follicular carcinoma. These results
provide a molecular classification
system for thyroid tumors and this in
turn provides a more accurate
diagnostic tool for the clinician
managing patients with suspicious
thyroid lesions. In addition to
diagnostics, this invention can be used
in the staging of thyroid malignancies
by measuring changes in DET gene and
protein expression relative to reference
cells. Finally, this invention can also be
used in the discovery of therapeutic
agents through the detection in changes
of DET gene and protein levels prior to
and after treatment.
The prospective exclusive license and
any further license applications
received as objections to this Notice of
Intent to Grant an Exclusive License,
will be royalty bearing and will comply
with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The
prospective exclusive license may be
granted unless within thirty (30) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Any additional applications for a
license in the field of use filed in
response to this notice will be treated as
objections to the grant of the
contemplated exclusive license.
E:\FR\FM\19JYN1.SGM
19JYN1
42505
Federal Register / Vol. 77, No. 139 / Thursday, July 19, 2012 / Notices
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 13, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–17497 Filed 7–18–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5602–N–05]
Notice of Proposed Information
Collection: Comment Request Notice
of Application for Designation as a
Single Family Foreclosure
Commissioner
AGENCY:
Office of the General Counsel,
HUD.
ACTION:
Notice.
The proposed information
collection requirement described below
will be submitted to the Office of
Management and Budget (OMB) for
review, as required by the Paperwork
Reduction Act. The Department is
soliciting public comments on the
subject proposal.
DATES: Comments Due Date: September
17, 2012.
SUMMARY:
Interested persons are
invited to submit comments regarding
this proposal. Comments should refer to
the proposal by name and/or OMB
Control Number and should be sent to:
Reports Liaison Officer, Office of
General Counsel, Department of
Housing and Urban Development, 451
7th Street SW., Room 10276,
Washington, DC 20410–0500.
FOR FURTHER INFORMATION CONTACT:
Sherece Tolbert, Deputy Assistant
General Counsel, Single Family
Mortgage Division, Office of General
Counsel, Department of Housing and
Urban Development, 451 7th Street SW.,
Room 9240, Washington, DC 20410–
0500, telephone (202–708–0080) (this is
not a toll-free number).
SUPPLEMENTARY INFORMATION: The
Department is submitting the proposed
information collection to OMB for
review, as required by the Paperwork
Reduction Act of 1995 (44 U.S.C.
Chapter 35, as amended).
This Notice is soliciting comments
from members of the public and
affecting agencies concerning the
proposed collection of information to:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information; (3) Enhance the quality,
utility, and clarity of the information to
ADDRESSES:
be collected; and (4) Minimize the
burden of the collection of information
on those who are to respond; including
through the use of appropriate
automated collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
This Notice also lists the following
information:
Title of Proposal: Notice of
Application for Designatin As a Single
Family Foreclosure Commissioner (SF
Mortgage Foreclosure Act of 1994).
OMB Control Number, if applicable:
2510–0012.
Description of the need for the
information and proposed use: Under
the Single Family Mortgage Foreclsoure
Act of 1994, HUD may exercise a
nonjudicial Power of Sale of single
family HUD-held mortgages and may
appoint Foreclsoure Commissioners to
do this. HUD needs the Notice and
resulting appliations for compliance
with the Act’s requirements that
commissioners be qualified. Most
respondents will be attorneys, but
anyone may apply.
Agency form numbers, if applicable:
None.
Members of affected public: Business
or Other For-Profit and Individuals or
Households.
Estimation of the total numbers of
hours needed to prepare the information
collection including number of
respondents, frequency of response, and
hours of response:
Number of respondents
Frequency of response
Hours per response
Total burden hours
30
1
.5
15
Status of the proposed information
collection: Reinstatement of collection.
Authority: The Paperwork Reduction Act
of 1995, 44 U.S.C. Chapter 35, as amended.
Dated: July 16, 2012.
Camille E. Acevedo,
Associate General Counsel for Legislation and
Regulations.
[FR Doc. 2012–17637 Filed 7–18–12; 8:45 am]
BILLING CODE 4210–67–P
DEPARTMENT OF THE INTERIOR
Bureau of Land Management
[LLNVE03000 L51100000.GN0000.
LVEMF1201550.241A; NVN–91032; MO#
4500035419; TAS: 14X5017]
Notice of Intent To Prepare an
Environmental Impact Statement for
the Proposed Long Canyon Mine
Project, Elko County, NV
Bureau of Land Management,
Interior.
ACTION: Notice of intent.
emcdonald on DSK67QTVN1PROD with NOTICES
AGENCY:
In compliance with the
National Environmental Policy Act of
1969 (NEPA), as amended, and the
Federal Land Policy and Management
Act (FLPMA) of 1976, as amended, the
Bureau of Land Management (BLM)
Wells Field Office, Elko, Nevada,
SUMMARY:
VerDate Mar<15>2010
15:07 Jul 18, 2012
Jkt 226001
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
intends to prepare an Environmental
Impact Statement (EIS) for the Long
Canyon Mine, and by this notice is
announcing the beginning of the
scoping process to solicit public
comments and identify issues.
This notice initiates the public
scoping process for the EIS. Comments
on issues may be submitted in writing
until September 4, 2012. The date(s) and
location(s) of any scoping meetings will
be announced at least 15 days in
advance through local media,
newspapers, and the BLM Web site at:
www.blm.gov/rv5c. In order to be
included in the Draft EIS, all comments
must be received prior to the close of
the scoping period. The BLM will
provide additional opportunities for
public participation upon publication of
the Draft EIS.
DATES:
E:\FR\FM\19JYN1.SGM
19JYN1
]]>Agencies
[Federal Register Volume 77, Number 139 (Thursday, July 19, 2012)]
[Notices]
[Pages 42504-42505]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-17497]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Development of a
Diagnostic Tool for Diagnosing Benign Versus Malignant Thyroid Lesions
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in PCT
Patent Application No. PCT/US2005/12289, U.S. Patent No. 7,901,881,
U.S. Patent Application No. 13/024,845 and foreign equivalents thereof
entitled ``Diagnostic Tool for Diagnosing Benign Versus Malignant
Thyroid Lesions'' (HHS Ref. No. E-124-2004/0,1,2) and PCT Patent
Application No. PCT/US2008/010139 and U.S. Patent Application No. 12/
675,209 entitled ``Diagnostic Tool for Diagnosing Benign Versus
Malignant Thyroid Lesions'' (HHS Ref. No. E-326-2007/0) to Veracyte,
Inc., which is located in San Francisco, California. The patent rights
in these inventions have been assigned to the United States of America.
Other than license applications submitted as objections to this
Notice of Intent to Grant an Exclusive License, no further license
applications will be considered for the exclusive field of use set
forth below if Veracyte, Inc. is granted an exclusive license pursuant
to this Notice of Intent to Grant an Exclusive License. The prospective
exclusive license territory may be worldwide and the field of use may
be limited to the use of Licensed Patent Rights for the diagnosis and
prognosis of thyroid cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
August 20, 2012 will be considered, in addition to the current non-
exclusive applications under consideration, for the prospective license
territory and field of use to be granted under the contemplated
exclusive patent license.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Whitney A. Hastings, Ph.D., Licensing
and Patenting Manager, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220;
Email: hastingw@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This technology is based on the discovery of
differentially expressed thyroid (DET) genes and their encoded proteins
whose expression levels can be correlated to benign or malignant states
in a thyroid cell. Specifically, this data arose from a microarray
analysis of genes expressed in the eight subtypes of thyroid tumors
that are typically difficult to diagnose by cytology of fine needle
aspiration (FNA) biopsies. Analysis of the (DET) genes led to the
development of 6 gene and 10 gene models that distinguish benign vs.
malignant papillary thyroid tumors. Subsequently, a 72 gene model has
been developed for diagnosing less common forms of thyroid cancer such
as follicular carcinoma. These results provide a molecular
classification system for thyroid tumors and this in turn provides a
more accurate diagnostic tool for the clinician managing patients with
suspicious thyroid lesions. In addition to diagnostics, this invention
can be used in the staging of thyroid malignancies by measuring changes
in DET gene and protein expression relative to reference cells.
Finally, this invention can also be used in the discovery of
therapeutic agents through the detection in changes of DET gene and
protein levels prior to and after treatment.
The prospective exclusive license and any further license
applications received as objections to this Notice of Intent to Grant
an Exclusive License, will be royalty bearing and will comply with the
terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless within thirty (30) days from
the date of this published notice, the NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Any additional applications for a license in the field of use filed
in response to this notice will be treated as objections to the grant
of the contemplated exclusive license.
[[Page 42505]]
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: July 13, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-17497 Filed 7-18-12; 8:45 am]
BILLING CODE 4140-01-P
